Table 2.
Clinical factors.
| Clinical factors | Training cohort (n=91) | p | Testing cohort (n=40) | p | ||
|---|---|---|---|---|---|---|
| Type1 (n=42) | Type2 (n=49) | Type1 (n=18) | Type2 (n=22) | |||
| Gender | 0.121 | 0.579 | ||||
| Male | 35 (83%) | 34 (69%) | 16 (89%) | 21 (95%) | ||
| Female | 7 (17%) | 15 (31%) | 2 (11%) | 1 (5%) | ||
| Age (years) | 57.4 ± 12.2 | 58.8 ± 12.6 | 0.571 | 56.7 ± 12.4 | 58.1 ± 14.3 | 0.693 |
| Maximum diameter (cm) | 3.5 ± 2.0 | 6.0 ± 3.5 | <0.001 | 3.6 ± 2.2 | 6.6 ± 2.7 | 0.001 |
| Shape | 0.001 | <0.001 | ||||
| Round | 38 (90%) | 29 (59%) | 17 (94%) | 9 (41%) | ||
| Not round | 4(10%) | 20 (41%) | 1 (6%) | 13 (59%) | ||
| Location | 0.174 | 0.356 | ||||
| Left | 18 (43%) | 28 (57%) | 8 (44%) | 13 (59%) | ||
| Right | 24 (57%) | 21 (43%) | 10 (56%) | 9 (41%) | ||
| Boundary | <0.001 | 0.004 | ||||
| Clear | 41 (98%) | 28 (57%) | 16 (89%) | 10 (45%) | ||
| Blurred | 1 (2%) | 21 (43%) | 2 (11%) | 12 (55%) | ||
| Calcification | 0.004 | 0.427 | ||||
| Present | 4 (10%) | 17 (35%) | 2 (11%) | 5 (23%) | ||
| Absent | 38 (90%) | 32 (65%) | 16 (89%) | 17 (77%) | ||
| Necrosis | <0.001 | <0.001 | ||||
| Present | 6 (14%) | 26 (53%) | 2 (11%) | 16 (73%) | ||
| Absent | 36 (86%) | 23 (47%) | 16 (89%) | 6 (27%) | ||
| Renal vein invasion | 0.003 | 0.011 | ||||
| Present | 0 (0) | 9 (18%) | 0 (0) | 7 (32%) | ||
| Absent | 42 (100%) | 40 (82%) | 18 (100%) | 15 (68%) | ||
| Lymph node metastasis | 0.001 | 0.005 | ||||
| Present | 0 (0) | 12 (24%) | 0 (0) | 8 (36%) | ||
| Absent | 42 (100%) | 37 (76%) | 18 (100%) | 14 (64%) | ||
| TEV1 (HU) | 18.5 ± 17.4 | 27.4 ± 32.5 | 0.063 | 13.4 ± 7.3 | 29.8 ± 31.5 | 0.121 |
| TEV2 (HU) | 32.0 ± 21.3 | 38.6 ± 23.3 | 0.068 | 28.2 ± 11.4 | 43.1 ± 30.1 | 0.178 |
| REV1 | 0.19 ± 0.16 | 0.28 ± 0.24 | 0.058 | 0.19 ± 0.20 | 0.30 ± 0.28 | 0.103 |
| REV2 | 0.28 ± 0.28 | 0.33 ± 0.17 | 0.014 | 0.23 ± 0.12 | 0.42 ± 0.49 | 0.092 |
TEV, tumour enhancement value; REV, relative enhancement value; 1, corticomedullary phase; 2, nephrographic phase.